hematology and oncology
Hypereosinophilic Syndrome
Prognosis for Hypereosinophilic Syndrome
Death usually results from organ, particularly cardiac, dysfunction. Cardiac involvement is not predicted by the degree or duration of eosinophilia. Prognosis varies depending on response to therapy. Response toimatinibimproves the prognosis among patients with theFIP1L1/PDGFRA-associated fusion gene and other responsive gene fusions. 